Pharmacovigilance using observational/longitudinal databases and web-based information
A. Lawrence Gould
Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA, 19486, USA
Search for more papers by this authorA. Lawrence Gould
Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA, 19486, USA
Search for more papers by this authorA. Lawrence Gould
Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA 19486, USA
Search for more papers by this authorSummary
Spontaneous reporting databases are convenient sources of information for identifying potential toxicities of medical products, but are subject to deficiencies that limit the interpretability of analyses based on the data they contain. This chapter describes approaches that are variations of traditional epidemiologic and pharmacovigilance approaches for systematically exploring conventional databases of accumulated health information. These approaches differ from conventional analyses of spontaneous reporting databases and analyses of observational databases primarily in the source of the informational substrate used for the analyses and in the techniques needed to put this material into a form amenable to signal-detection analysis. An evaluation of various detection methods, reporting odds ratio, temporal pattern discovery, incidence rate ratio (IRR), Longitudinal Gamma Poisson Shrinker (LGPS), hierarchical Bayes, case–control, and self-controlled case series (SCCS) applied to seven European electronic health databases with prespecified positive and negative controls demonstrated area under the curves (AUCs) in the range of 0.7–0.8.
References
- Gould, A. L., Lystig, T.C., Lu, Y., Fu, H., and Ma, H., (2014) Methods and isues to consider for detection of safety signals from spontaneous reporting databases. Report of the DIA Bayesian Safety Signal Detection Working Group. Therapeutic Innovation and Regulatory Science. Published online 8 May 2014.
- Hauben M, Madigan D, Gerrits C, Walsh L, van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opinion in Drug Safety 2005; 4: 929–948.
- Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Zeng P. How well do various health outcome definitions identify appropriate cases in observational studies? Drug Safety 2013; 36: S27–S32.
- Madigan D, Stang PE, Berlin JA, Schuemie MJ, Overhage JM, Suchard MA, DuMouchel W, Hartzema AG, Ryan PB. A systematic statistical approach to evaulating evidence from observational studies. Annual Review of Statistics 2014; 1: 11–39.
- Trifiro G, Fourrier-Reglat A, Sturkenboom MC, et al., The EU-ADR project: preliminary results and perspective. Studies in Health Technologies and Informatics 2009; 148: 43–49.
- Harpaz R, Vilar S, DuMouchel W, Salmasian H, Haerian K, Shah NH, Chase HS, Friedman C. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. Journal of the American Medical Informatics Association 2013; 20: 413–419.
- Reich CG, Ryan PB, Schuemie MJ. Alternative outcome definitions and their effect on the performance of methods for observational studies. Drug Safety 2013; 36: S181–S193.
- Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Safety 2013; 36: S33–S47.
- Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Safety 2013; 36: S171–S180.
- Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Statistical Methods in Medical Research 2013; 22: 39–56.
- DuMouchel W, Ryan PB, Schuemie MJ, Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Safety 2013; 36: S123–S132.
- Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiology and Drug Safety 2011; 20: 292–299.
- DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system (Disc: p190–202). American Statistician 1999; 53: 177–190.
- Schuemie MJ, Madigan D, Ryan PB. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Safety 2013; 36: S133–S142.
- Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Safety 2013; 36: S83–S93.
- Nicholas JM, Grieve AP, Gulliford MC. Within-person study designs had lower percision and greather susceptibility to bias because of trends in exposure than cohort and nested case-control designs. Journal of Clinical Epidemiology 2012; 65: 384–393.
- Simpson SE, Madigan D, Zorych I, Schuemie MJ, Ryan PB, Suchard MA. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics 2013; 69: 893–902.
- Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Safety 2013; 36: S73–S82.
- Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Safety 2013; 36: S95–S106.
- Graham PL, Mengerson K, Morton AP. Confidence limits for the ratio of two rates based on likelihood scores. Statistics in Medicine 2003; 22: 2071–2083.
- Noren GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Safety 2013; 36: S107–S121.
- Norén, G. N., Bate, A., Hopstadius, J., Star, K., and Edwards, I. R. Temporal Pattern Discovery for Trends and Transient Effects: Its Application to Patient Records, ACM, Washington, DC, 2008.
- Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Mining and Knowledge Discovery 2010; 20: 361–387.
-
Jin H, Chen J, Kelman C, He H, McAullay D, O'Keefe CM. Mining unexpected associations for signalling potential adverse drug reactions from administrative health databases. In W.K. Ng, M. Kutsuregawa, and J. Li eds. Advances in Knowledge Discovery and Data Mining: 10th Pacific-Asia Conference, PADKK 2006, Lecture Notes in Artificial Intelligence 3918, Springer-Verlag, Berlin, 2006, pp. 867–876.
10.1007/11731139_101 Google Scholar
- Jin H, Chen J, He H, Kelman C, McAullay D, O'Keefe CM. Signaling potential adverse drug reactions from administrative health databases. IEEE Transactions on Knowledge and Data Engineering 2010; 22: 839–852.
- Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson J, Hubbard R. Comparison of algorithms that detect drug side effects using electronic healthcare databases. Soft Computing 2013; 17: 2381–2397.
- van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety 2002; 11: 3–10.
- Van Holle L, Bauchau V. Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset based algorithm. Pharmacoepidemiology and Drug Safety 2014; 23: 178–185.
- Eysenbach G. Infodemiology and infoveillancd: framework for an emerging set of public health informatics methods to analyze search, communication and publication behavior on the internet. Journal of Medical Internet Research 2009; 11: e11.
- Eysenbach G. Infodemiology and infoveillance. Tracking online health information and cyberbehavior for public health. American Journal of Preventive Medicine 2011; 40: S154–S158.
- Benton A, Ungar L, Hill S, Hennessy S, Mao J, Chung A, Leonard CE, Holmes JH. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. Journal of Biomedical Informatics 2011; 44: 989–996.
- White RW, Tatonetti NP, Shah NH, Altman RB, Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. Journal of the American Medical Informatics Association 2013; 20: 404–408.
- Yom-Tov E, Gabrilovich E. Postmarket drug surveillance without rrial costs: discovery of adverse drug reactions rhrough large-scale analysis of web search queries. Journal of Medical Internet Research 2013; 15: e124.
- Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Molecular Systems Biology 2010; 6: 343.
- Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal genertion from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety 2001; 10: 483–486.
- Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiology and Drug Safety 2004; 13: 519–523.
- Berry SM, Berry DA. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics 2004; 60: 418–426.
- Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: The self-controlled case series method. Statistics in Medicine 2006; 25: 1768–1797.
- Schuemie MJ, Coloma PM, Straatman H, Herings RMC, Trifiro G, Matthews JN, Prieto-Merino D, Molokhia M, Pedersen L, Gini R, Innocenti F, Mazzaglia G, Picelli G, Scotti L, van der Lei J, Starkenboom MCJM. Using electronic health care records for drug safety signal detection. Medical Care 2012; 50: 890–897.
- Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identifcation and analysis system. Drug Safety 2013; 36: S59–S72.
- Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, Reich CG, Schuemie MJ, Madigan D. A comparison of the empirical performance of methods for a risk identification system. Drug Safety 2013; 36: S143–S158.
- Schuemie MJ, Gini R, Coloma PM, Straatman H, Herings RMC, Pedersen L, Innocenti F, Mazzaglia G, Picelli G, van der Lei J, Sturkenboom MCJM. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Safety 2013; 36: S159–S169.